There are currently 66 clinical trials in Arlington, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Clinical Research Institute, Texas Retina Associates, GSK Investigational Site and Texas Clinical Research Institute, Llc. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
NCT05577715
Recruiting
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/17/2023
Locations: Texas Oncology - Arlington North, Arlington, Texas
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
NCT03471117
Recruiting
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function. The goal of this study is to determine whether a short-term treatme... Read More
Gender:
All
Ages:
Between 35 years and 70 years
Trial Updated:
05/09/2023
Locations: University of Texas at Arlington, Arlington, Texas
Conditions: Chronic Kidney Diseases
Register for Updates
Know and Own Your Movement-related Metrics Via Wearable Devices
NCT05490641
Recruiting
This study aims to promote daily physical activity in cancer survivors who are at high risk for type 2 diabetes (T2D) by using a personalized biological-based feedback strategy. T2D is one of the most common co-occurring conditions in cancer survivors and can worsen cancer-related health outcomes, especially in those who are insufficiently active. The investigators hypothesize that seeing the immediate impacts of exercise on their biological status will motivate cancer survivors to exercise. The... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2023
Locations: The University of Texas at Arlington, Arlington, Texas
Conditions: Cancer, Survivorship
Register for Updates
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (AMD) or Subjects With Diabetic Macular Edema (DME)
NCT05387837
Recruiting
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2023
Locations: Texas Retina Associates - Arlington, Arlington, Texas
Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Register for Updates
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Texas Clinical Research Institute, Arlington, Texas
Conditions: Non Alcoholic Steatohepatitis (NASH)
Register for Updates
Creating Physical Objects With 3D Printers to Stimulate Reminiscing for Memory Loss [2 R44 AG049548-02A1]
NCT03625973
Recruiting
In 2013 an estimated 5 million people age 65 and older had Alzheimer's disease. Longer life spans and aging baby boomers will cause this number to grow rapidly. More than 50% of residents in assisted living and nursing homes have some form of dementia or cognitive impairment and the number is increasing every day. As a form of person-centered, non-pharmacological dementia care, Reminiscence Therapy (RT) holds considerable promise. Improvements in mood, quality of life, social interaction, cogni... Read More
Gender:
All
Ages:
All
Trial Updated:
04/18/2022
Locations: University of Texas Arlington, Arlington, Texas
Conditions: Dementia
Register for Updates